

May 28, 2014

Dear Manufacturers,

I am writing on behalf of Swedish Covenant Hospital (340B ID#DSH140114) to inform manufacturers that Swedish Covenant Hospital recently underwent an audit by the Health Resources and Services Administration (HRSA) of Swedish Covenant Hospital's compliance with 340B Drug Pricing Program (340B Program) requirements.

As background, Swedish Covenant Hospital qualified for the 340B Program as a disproportionate share hospital located in Chicago, Illinois, and has participated in the 340B Program since July 1, 2004.

Through the audit process, Swedish Covenant Hospital was found to have non-compliance within the 340B Program and was responsible for repayment as a result of the following finding:

Swedish dispensed 340B drugs to ineligible individuals as prohibited by 42 USC 256b(a)(5)(B).

Swedish Covenant Hospital has identified all affected manufacturers and has contacted each to notify them of these violations to begin a dialogue on a method for repayment to affected manufacturers. If manufacturers have not received notification from Swedish Covenant Hospital and believe repayment may be owed for the violations described in this letter, or if you have any questions or comments regarding the violations described in this letter, please contact:

Ramesh Patel, Pharm.D.
Senior Director, Pharmacy Services and Clinical Research
Swedish Covenant Hospital
5145 N. California Ave.
Chicago, IL 60625
773-878-8200 ext. 5379
rpatel@schosp.org

Yours truly,

Mark Newton
President and Chief Executive Officer